1. A short plasma half life does not predict less drug accumulation;Sebaldt, R.J.;J Rheumatol,1986
2. Piroxicam pharmacokinetics: recent clinical results relating kinetics and plasma levels to age, sex and adverse be effective if remission was induced in patients group; controls should have the same potential for effects;Hobbs, D.C.;Am Med; 81(suppl 5B): 22-8. with chronic arthritis or if palindromic attacks were prevented in patients whose rheumatism had exposure to the study drugs as cases. Secondly, there was apparently no controlling for age or,1986
3. Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events;Rugstad, H.E.;CliaRhewatol,1986
4. Non-steroidal anti-inflammatory drugs and the out known peptic ulceration, but an appropriate taking a non-steroidal anti-inflammatory drug, and kidney. BrMedJ 1986; 292: 1621-2. control group would have been matched for age and sex. For example, it may be that older patients our local figures show that piroxicam is associated with twice the expected number ofcases compared;ML'E, Orme
5. Single dose and steady state pharmacokinetics of piroxicam in elderly vs young adults;Darragh, A.; Gordon, A.J.; O'Byrne, H.; Hobbs, D.; Casey, E.;EurJ Clin Pharmacol,1985